The international law firm Milbank, Tweed, Hadley & McCloy LLP advised gruppeH GmbH on the sale of all shares in humediQ global GmbH ("humediQ") to Varian Medical Systems, Inc. ("Varian"), a global leader in the radiotherapy of tumor diseases.
humediQ, headquartered in Munich, Germany, is focused on the development, production and sales of hardware and software solutions for quality assurance in radiotherapy. The key product of humediQ is IDENTIFY, an automated patient identification, positioning and motion manage-ment system for radiation therapy.
Varian, headquartered in Palo Alto, California, is a leader in developing and delivering hardware and software products for the treatment of cancer with radiotherapy, stereotactic radiosurgery, stereotactic body radiotherapy (SBRT), proton therapy, and brachytherapy. Varian employs approximately 6,500 people around the world.
A Milbank team headed by partner Martin Erhardt advised gruppeH GmbH on all legal aspects.
Advisor to gruppeH GmbH: Milbank, Tweed Hadley & McCloy LLP
Martin Erhardt (lead), Thomas Kleinheisterkamp (Tax, Munich), Michael Pujol (Corporate/M&A, Munich), Alexander Rinne (Antitrust, Munich), Nikolas Koutsós (Finance, Frankfurt), Florian Mader (Corporate/M&A, Munich).
